NASDAQ:ARVN

Arvinas (ARVN) Stock Price, News & Analysis

Arvinas logo
$6.68 -0.08 (-1.18%)
As of 01:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Arvinas Stock (NASDAQ:ARVN)

Advanced

Key Stats

Today's Range
$6.52
▼
$6.86
50-Day Range
$6.41
▼
$8.71
52-Week Range
$6.33
▼
$14.51
Volume
264,419 shs
Average Volume
837,769 shs
Market Capitalization
$437.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.18
Consensus Rating
Moderate Buy

Company Overview

Arvinas, Inc. is a biotechnology company based in New Haven, Connecticut, that develops medicines using targeted protein degradation. Founded in 2013, the company applies its PROTAC technology to direct disease-related proteins for removal by the body’s natural protein-disposal system.

Its research focuses primarily on cancer, including investigational therapies designed to target estrogen and androgen receptors. The company’s programs include vepdegestrant, an estrogen receptor degrader being developed with Pfizer for certain forms of breast cancer, as well as androgen receptor degraders being studied for prostate cancer.

Arvinas’s drug candidates are investigational and have not all been approved for commercial use. Through research and development and collaborations with other companies, it seeks to advance targeted protein degradation as an approach to treating serious diseases.

AI Generated. May Contain Errors.

Arvinas Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

ARVN MarketRank™: 
2.434865639065 of 5 stars

Arvinas scored higher than 49% of companies evaluated by MarketBeat, and ranked 1023rd out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 6 buy ratings, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    Arvinas has a consensus price target of $15.18, representing about 126.7% upside from its current price of $6.70.

  • Amount of Analyst Coverage

    Arvinas has only been the subject of 3 research reports in the past 90 days.

  • Read more about Arvinas' stock forecast and price target.
  • Earnings Growth

    Earnings for Arvinas are expected to decrease in the coming year, from $0.27 to ($3.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arvinas is -27.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arvinas is -27.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arvinas has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.47% of the float of Arvinas has been sold short.
  • Short Interest Ratio / Days to Cover

    Arvinas has a short interest ratio ("days to cover") of 7.59.
  • Change versus previous month

    Short interest in Arvinas has recently increased by 2.84%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Arvinas does not currently pay a dividend.

  • Dividend Growth

    Arvinas does not have a long track record of dividend growth.

  • News Sentiment

    Arvinas has a news sentiment score of -0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • Search Interest

    1 people have searched for ARVN on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Arvinas to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,476.00 in company stock.

  • Percentage Held by Insiders

    7.30% of the stock of Arvinas is held by insiders.

  • Percentage Held by Institutions

    95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arvinas' insider trading history.
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARVN Stock News Headlines

Arvinas to Present at Jefferies Global Healthcare Conference
Arvinas Holding Company (ARVN) Receives a Buy from Barclays
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
Arvinas (ARVN) Q3 2026 Earnings Call Transcript
What To Expect From Arvinas Inc (ARVN) Q3 2026 Earnings
Arvinas Q3 2026 earnings preview
See More Headlines

ARVN Stock Analysis - Frequently Asked Questions

Arvinas' stock was trading at $11.86 at the beginning of 2026. Since then, ARVN stock has decreased by 43.5% and is now trading at $6.6960.

Arvinas, Inc. (NASDAQ:ARVN) released its quarterly earnings data on Tuesday, November, 3rd. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.10. The business's revenue for the quarter was down 98.8% on a year-over-year basis.
Read the conference call transcript
.

Arvinas' Board of Directors approved a stock buyback plan on Wednesday, September 17th 2025, which permits the company to buy back $100 million in shares, according to EventVestor. This means that the company could reacquire up to 17.9% of its shares through open market purchases. Shares buyback plans are often a sign that the company's leadership believes its stock is undervalued.

Arvinas (ARVN) raised $112 million in an initial public offering on Thursday, September 27th 2018. The company issued 7,500,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Top institutional investors of Arvinas include State Street Corp (3.17%), Goldman Sachs Group Inc. (1.23%), Algert Global LLC (0.70%) and Caxton Associates LLP (0.24%). Insiders that own company stock include John G Houston, Randy Teel, Noah Berkowitz, Andrew Saik, Sean A Cassidy, Ian Taylor, Briggs Morrison, Ronald Peck and David K Loomis.
View institutional ownership trends
.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include NVIDIA (NVDA), Tesla (TSLA), NIO (NIO), Intel (INTC), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Salesforce (CRM).

Company Calendar

Last Earnings
11/03/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ARVN
CIK
1655759
Fax
N/A
Employees
246
Year Founded
2013

Price Target and Rating

High Price Target
$21.00
Low Price Target
$10.00
Potential Upside/Downside
+124.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$80.80 million
Net Margins
-3.45%
Pretax Margin
-3.23%
Return on Equity
-2.00%
Return on Assets
-1.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.39
Quick Ratio
8.39

Sales & Book Value

Annual Sales
$262.60 million
Price / Sales
1.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.85 per share
Price / Book
0.86

Miscellaneous

Outstanding Shares
65,490,000
Free Float
60,705,000
Market Cap
$442.38 million
Optionable
Optionable
Beta
1.81

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:ARVN) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners